戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 in wild-type and Fgf23(-/-) mice, it reduces serum phosphate.
2  rats over 8 hours increased FEPi, decreased serum phosphate (1.95 +/- 0.1 to 1.53 +/- 0.09 mmol/l, P
3 FGF23 neutralization significantly increased serum phosphate, 1,25(OH)2D and BUN, and decreased serum
4  we randomly assigned 162 eligible patients (serum phosphate =6.0 to <10.0 mg/dl and a 1.5-mg/dl incr
5                 Dose-dependent elevations in serum phosphate, a manifestation of pharmacodynamic effe
6 this commentary touches on patients with low serum phosphate after acute hospitalization, those with
7  analysis of race, socioeconomic status, and serum phosphate among 2879 participants in the Chronic R
8                            The regulation of serum phosphate, an acknowledged risk factor for chronic
9 ar calcification is due, in part, to reduced serum phosphate, an important inducer of VSMC-mediated v
10 ing levels of FGF23, exhibited low levels of serum phosphate and 1,25(OH)(2)D, reduced expression of
11 ion, we observed dose-dependent increases in serum phosphate and aortic calcification associated with
12 remic mice had significantly lower levels of serum phosphate and attenuation of FGF23.
13                                      Whereas serum phosphate and calcium levels declined to normal by
14 ven the association between higher levels of serum phosphate and cardiovascular disease, further stud
15 esents a novel therapeutic approach to lower serum phosphate and FGF23 levels that will be tested in
16  may reduce dietary phosphate absorption and serum phosphate and FGF23 levels.
17  absorption is one modifiable determinant of serum phosphate and FGF23 levels.
18 rt independent associations between elevated serum phosphate and fibroblast growth factor 23 (FGF23)
19 measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, di
20                                       Normal serum phosphate and parathyroid hormone were observed in
21 ures of calcium homeostasis, except elevated serum phosphate and urine calcium levels in girls.
22 ctors are integrated to yield the measurable serum phosphate are only now beginning to be studied.
23                         Associations between serum phosphate, arterial stiffness, and left ventricula
24 dietary phosphorus intake to mild changes in serum phosphate because of the nature of the study desig
25 stages 3-5 have shown only modest changes in serum phosphate but evaluated morning phosphate.
26 rtial effectiveness of directly reducing the serum phosphate by a phosphate binder that had no skelet
27        Ablation of FGF23 results in elevated serum phosphate, calcium, and 1,25-dihydroxyvitamin D3 [
28                                              Serum phosphate, calcium, and fibroblast growth factor 2
29 6], p<0.001); this effect was independent of serum phosphate concentration but associated with urinar
30 The primary efficacy end point was change in serum phosphate concentration from baseline (randomizati
31 of renal calcium and phosphate and increased serum phosphate concentration in gsk3(KI) mice.
32 d trial assessed the effects of tenapanor on serum phosphate concentration in patients with hyperphos
33                             Normalization of serum phosphate concentration occurred in almost all pat
34     In multivariate Cox regression analysis, serum phosphate concentration remained a statistically s
35                    In Kaplan-Meier analysis, serum phosphate concentration was a significant predicto
36 and estimated GFR, each 1-mg/dl increment in serum phosphate concentration was associated with a 21%
37                        Each 0.5 mg/dl higher serum phosphate concentration was associated with greate
38                                          The serum phosphate concentration was higher in the postmeno
39                                              Serum phosphate concentration was significantly associat
40 ry end points were serum iPTH concentration, serum phosphate concentration, bone mineral density, vas
41  biosensor is also suitable to determine the serum phosphate concentration, with a recovery of 86-104
42  variability was explained by age, LVMI, and serum phosphate concentration.
43 osphate excretion, leading to an increase in serum phosphate concentration.
44              Within the normal range, higher serum phosphate concentrations are associated with cardi
45                                         Mean serum phosphate concentrations at baseline (after washou
46       We determined the circadian pattern of serum phosphate concentrations in CKD and whether it was
47 ly significant, dose-dependent reductions in serum phosphate concentrations in patients with hyperpho
48  socioeconomic status associates with higher serum phosphate concentrations irrespective of race.
49 st incomes or who were unemployed had higher serum phosphate concentrations than participants with th
50        Current guidelines recommend lowering serum phosphate concentrations toward normal.
51                                              Serum phosphate concentrations were within the normal ra
52                  We examined associations of serum phosphate concentrations with vascular and valvula
53                        In conclusion, higher serum phosphate concentrations, although still within th
54            CRD mice had significantly higher serum phosphate, creatinine, and cystatin C levels than
55 lities and are independently associated with serum phosphate, Fe(PO4), and calcitriol deficiency.
56 2% to 2.2 +/- 1.1% (P < 0.05), and increased serum phosphate from 2.9 +/- 0.2 mg/dl to 4.1 +/- 0.2 mg
57                                         High serum phosphate has been identified as an important cont
58              The effects of these factors on serum phosphate have major implications for what is unde
59 rs may be a therapeutic approach to modulate serum phosphate in CKD.
60 vents and mortality strongly correlates with serum phosphate in individuals with CKD.
61  disordered skeletal modeling, also reducing serum phosphate in the process.
62 notype of predialysis kidney disease: normal serum phosphate, increased fractional excretion of phosp
63                                              Serum phosphate independently predicts cardiovascular mo
64 rum calcification propensity included higher serum phosphate, ionized calcium, increased bone osteocl
65 ve study are the first to show that a higher serum phosphate is a predictor of mortality in patients
66                       A circadian pattern of serum phosphate is observed in CKD with lowest concentra
67  and the mechanism by which the elevation of serum phosphate is thought to induce hypocalcemia is dis
68 phosphate excretion and serum FGF-23 but not serum phosphate, klotho, vitamin D, or cardiovascular-re
69 apanor provided dose-dependent reductions in serum phosphate level from baseline (least squares mean
70 anced, the factors determining regulation of serum phosphate level remain enigmatic.
71 study was to investigate whether an elevated serum phosphate level was an independent predictor of mo
72  Patients in the low-phosphate group (median serum phosphate level, 2.0 mg per deciliter [0.6 mmol pe
73 ent PHEX protein/enzyme leads to a decreased serum phosphate level, which cause mineralization defect
74 en identified as significant contributors to serum phosphate level.
75                            After adjustment, serum phosphate levels >3.5 mg/dl were associated with a
76 m magnesium levels (P = 1.2 * 10(-3)), lower serum phosphate levels (P = 2.8 * 10(-7)) and lower bone
77 U/HP group, and no differences were noted in serum phosphate levels among groups.
78        We identified 16 patients who had low serum phosphate levels and 8 patients who had normal ser
79 n uremic patients, is highly correlated with serum phosphate levels and cardiovascular mortality.
80 s were independent of baseline and follow-up serum phosphate levels and persisted in analyses that ex
81 n = 3186) patients matched by their baseline serum phosphate levels and propensity score of receiving
82        In patients on hemodialysis, elevated serum phosphate levels are an independent predictor of m
83     Although we also observed differences in serum phosphate levels by race, income modified this rel
84                                     Elevated serum phosphate levels have been linked with vascular ca
85           We examined mortality according to serum phosphate levels in a prospective cohort of 10,044
86                         Genetically reducing serum phosphate levels in klotho(-/-) mice by generating
87  FGF-23 may contribute to maintaining normal serum phosphate levels in the face of advancing CKD but
88                                              Serum phosphate levels in the highest quartile (>5.5 mg
89 , and although elevated FGF23 helps maintain serum phosphate levels in the normal range in CKD, it ma
90                                     Elevated serum phosphate levels were independently associated wit
91                                              Serum phosphate levels were lower in dialysis patients u
92                                       Higher serum phosphate levels within the normal range were asso
93 osphate levels and 8 patients who had normal serum phosphate levels, all of whom were receiving imati
94 -)/klotho(-/-) mice are viable and have high serum phosphate levels, similar to Fgf23(-/-) and klotho
95 erestingly, the null mice also displayed low serum phosphate levels, while calcium levels remained un
96 y with each subsequent 0.5-mg/dl increase in serum phosphate levels.
97 e binder sevelamer carbonate further reduced serum phosphate levels.
98 -deficient mice or alphaKL-null mice reduced serum phosphate levels.
99 ients with chronic kidney disease and normal serum phosphate levels.
100 nd resorption), even in patients with normal serum phosphate levels.
101 nction declines; is linearly associated with serum phosphate levels; is associated with increased pho
102 tudies will need to determine whether excess serum phosphate may explain disparities in kidney diseas
103  were available for analysis, and 3490 had a serum phosphate measurement during the previous 18 mo.
104                     In contrast, neither the serum phosphate nor 1,25(OH)(2)D levels were altered in
105  comp/hom and het individuals with decreased serum phosphate (odds ratio [OR], 0.75, 95% confidence i
106 l density (BMD), osteomalacia, and decreased serum phosphate (P(i)).
107 n were studied prospectively with respect to serum phosphate, phosphate requirements, as well as rena
108 nts with a renal transplant and suggest that serum phosphate provides additional, independent, progno
109                           The values of age, serum phosphate, pulse wave velocity, left ventricular m
110                            The physiology of serum phosphate regulation and the mechanism by which th
111 hosphate excretion and hypophosphaturia, but serum phosphate remained unchanged.
112 cular, and biochemical covariates, including serum phosphate, risk of death among patients in the low
113 , estimated GFR, albuminuria, serum calcium, serum phosphate, serum bicarbonate, and serum albumin (C
114 onship: Blacks had 0.11 to 0.13 mg/dl higher serum phosphate than whites in the highest income groups
115                                              Serum phosphate was measured at baseline and prospective
116                                              Serum phosphate was significantly higher in those renal
117 tho(-/-) and klotho(-/-) mice does not lower serum phosphate, whereas in wild-type and Fgf23(-/-) mic
118 ogic studies suggest that mild elevations of serum phosphate within the normal range are associated w

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top